title: Associations between autofluorescence abnormalities and visual acuity in idiopathic macular telangiectasia type 2: MacTel project report number 5.
abstract: OBJECTIVE
  The aim of this study was to determine whether typical abnormalities seen on autofluorescence (AF) imaging in patients with macular telangiectasia (MacTel) type 2 are correlated with visual acuity at presentation and with progression of visual loss over a 2-year follow-up period.
  
  
  METHODS
  A subgroup of 218 patients (413 eyes) enrolled in the MacTel study that underwent AF imaging was included in the present study. Images were graded at the Moorfields Eye Hospital Reading Center. Recorded AF abnormalities at baseline and at 2 years included the presence of increased AF because of loss of masking at the central macula, localized decreased AF at the end of a retinal vessel, and large area of decreased AF. Best-corrected visual acuity was measured using the Early Treatment for Diabetic Retinopathy chart at baseline and after 2 years. Statistical associations were sought by means of a generalized linear model.
  
  
  RESULTS
  Presence of increased macular AF (P = 0.004), a large area of decreased AF (P < 0.001), or decreased AF at the end of a retinal vessel (P < 0.001) at baseline were significantly associated with worse best-corrected visual acuity. Presence of increased macular AF (P < 0.001) or of localized decreased AF at the end of a retinal vessel (P < 0.001) and the absence of a large area of decreased AF (P < 0.001) were predictive of a subtle but significant drop in best-corrected visual acuity at 2 years.
  
  
  CONCLUSIONS
  Increased central AF at baseline heralds worse best-corrected visual acuity and predicts further subtle visual loss in a period of 2 years, which, however, does not stand out from the overall slowly progressive natural history of the disease.
authors.affiliation: *Medical Retina Service, Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom; †Department of Research and Development, Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom; ‡Manchester Royal Eye Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; §UCL Institute of Ophthalmology, London, United Kingdom; ¶The EMMES Corporation, Rockville, Maryland; **Inherited Eye Disease, Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom; and ††NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Balaskas
authors.forename: Irene
authors.initials: I
authors.lastname: Leung
authors.forename: Ferenc B
authors.initials: FB
authors.lastname: Sallo
authors.forename: Traci E
authors.initials: TE
authors.lastname: Clemons
authors.forename: Alan C
authors.initials: AC
authors.lastname: Bird
authors.forename: Tunde
authors.initials: T
authors.lastname: Peto
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D061848:Optical Imaging; D011446:Prospective Studies; D058456:Retinal Telangiectasis / Q000175:diagnosis* / Q000503:physiopathology; D012171:Retinal Vessels / Q000473:pathology*; D014792:Visual Acuity / Q000502:physiology*